Level C· Early human research exploring benefitsProspective StudyPubMedOpen access

Why and how to use the body's own stem cells for regeneration in musculoskeletal disorders: a primer.

Furia JP., Lundeen MA., Hurd JL., Pearce DA., Alt C., Alt EU.

Prospective Study on Cartilage Damage, Tendon Injury, Scar, published in J Orthop Surg Res (2022) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
J Orthop Surg Res (2022)
Country
England
Reported sample size
—
Source database
PubMed
PMID
35062984
PMCID
PMC8781360
DOI
10.1186/s13018-022-02918-8
NCT
NCT03752827
Citations
17

Abstract (original English)

Background: Recently, the management of musculoskeletal disorders with the patients' own stem cells, isolated from the walls of small blood vessels, which can be found in great numbers in the adipose tissue, has received considerable attention. On the other hand, there are still misconceptions about these adipose-derived regenerative cells (ADRCs) that contain vascular-associated pluripotent stem cells (vaPS cells) in regenerative medicine. Methods: Based on our previous publications on this topic, we have developed a concept to describe the significance of the ADRCs/vaPS cells in the field of orthobiologics as briefly as possible and at the same time as precisely as possible. Results: The ADRCs/vaPS cells belong to the group of orthobiologics that are based on autologous cells. Because the latter can both stimulate a patient’s body's localized self-healing power and provide new cells that can integrate into the host tissue during the healing response when the localized self-healing power is exhausted, this group of orthobiologics appears more advantageous than cell-free orthobiologics and orthobiologics that are based on allogeneic cells. Within the group of orthobiologics that are based on autologous cells, enzymatically isolated, uncultured ADRCs/vaPS cells have several advantages over non-enzymatically isolated cells/microfragmented fat as well as over uncultured bone

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
Adipose TissueBone RegenerationCell- and Tissue-Based TherapyHumansMusculoskeletal DiseasesPluripotent Stem CellsRegenerative MedicineStem Cell TransplantationTransplantation, Autologous

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research